Evaluation of glycoprotein constituents in head and neck cancer patients undergoing radiotherapy

Head and Neck

Volumn 21, Issue 3, 1999, Pages 192-197

  Rawal, Rakesh M ^a   Patel, Prabhudas S ^a   Patel, Beena P ^a   Raval, Gira N ^a   Patel, Mintoo M ^a   Bhatavdekar, Jyotsna M ^a   Dixit, Sanjay A ^a   Patel, Devendra D ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Cancer; Glycoproteins; Head and neck; Radiotherapy; Seromucoid fraction; Sialic acid; Tumor markers

Indexed keywords

GLYCOPROTEIN; SIALIC ACID;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPECTROPHOTOMETRY; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; OROSOMUCOID; TUMOR MARKERS, BIOLOGICAL;

EID: 0032935127     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0347(199905)21:3<192::AID-HED2>3.0.CO;2-D     Document Type: Article

References (30)

1. Lopez-saez JJ, Senra-Varela A. Evaluation of lipid bound sialic acid (LSA) as a tumour marker. Int J Biol Markers 1995;10:174-179.
2. Stringou E, Chondros K, Kouvaris J, Kakari S, Papavassiliou K. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy. Anticancer Res 1992;12:251-255.
3. Emmelot P. Biochemical properties of normal and neoplastic cell surface - a review. Eur J Cancer 1973;9: 319-333.
4. Hakomori SI. Tumour associated carbohydrate antigen. Ann Rev Immunol 1984;2:103-126.
5. Alhadeff JA. Malignant cell glycoproteins and glycolipids. Crit Rev Oncol Hematol 1989;9:37-107.
6. Maity P, Das P, Roychowdhury J. Serum sialic acid level under different conditions including malignancy. Indian J Med Res 1983;78:137-140.
7. Correale M, Abbate I, Gargano G, et al. The determination of sialic acid in cancer patients. Minerva Med 1992; 83:427-431.
8. Schutter EM, Visser JJ, Van-Kamp GJ, et al. The utility of lipid-associated sialic acid (LASA or LSA) as s serum marker for malignancy. A review of the literature. Tumour Biol 1992;13:121-132.
9. Suresh MR. Classification of tumour markers. Anticancer Res 1996;16:2273-2277.
10. Xing RD, Wang ZS, Li CQ, Tang QY, Jiang CB, Zhang YZ. Total sialic acid as a tumour marker for oral cancer. Int J Biol Marker 1994;9:239-242.
11. Fischer F, Egg G. N-Acetylneuramic acid (sialic acid) as a tumour marker in head and neck cancer. HNO 1990;38: 361-363.
12. Xing RD, Chen RM, Wang ZS, Zhang YZ. Serum sialic acid levels in patients with oral and maxillofacial malignancy. J Oral-Maxillofac Surg 1991;49:843-847.
13. National Cancer Registry Programme. Biennial report 1988-89: an epidemiological study. New Delhi: ICMR, 1989:1-182.
14. Hermanek P, Sobin LH, editors. TNM classification of malignant tumours, 4th ed., UICC, Geneva; 1987.
15. Skoza L, Mohos S. Stable thiobarbituric acid chromophore with dimethyl sulphoxide. Biochem J 1976;159:457-462.
16. Katopodis N, Hirashaut Y, Nancy LG, Stock CC. Lipid associated sialic acid test for the detection of human cancer. Cancer Res 1982;42:5270-5275.
17. Winzler RJ. Determination of serum glycoproteins. In: Glick D, editor. Methods of biochemical analysis. Vol. II. New York: Interscience Publishers; 1955. p 279-311.
18. Hartee EF. Determination of proteins: a modification of Lowry method. Anal Biochem 1972;48:422-427.
19. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Caponigro F, Iaffaioli RV, Pagliarulo C, et al. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int J Biol Marker 1990;5:73-76.
21. Verazin G, Riley WM, Gregory J, Tautu C, Prorok JJ, Alhadeff JA. Serum sialic acid and carcinoembryonic levels in the detection and monitoring of colorectal cancer. Dis Colon Rectum 1990;33:139-142.
22. Meyer U, Dierig C, Katopodis N, De-Bruijn CH. The role of lipid associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow up of prostatic cancer. Anticancer Res 1993;13:1889-1894.
23. Kakari S, Stringon E, Toumbis M, et al. Five tumour markers in lung cancer: significance of total and "lipid" bound sialic acid. Anticancer Res 1991;11:2107-2110.
24. Bhuvarahamurthy V, Balasubramanian N, Vijaykumar S, Govindaswamy S. Effect of radiation on serum glycoproteins and glycosidases in patients with cervical carcinoma. Int J Gynaecol Obstet 1995;48:49-54.
25. Suer S, Sonmez H, Karaaslan I, Baloglu H, Kokoglu E. Tissue sialic acid and fibronectin levels in human prostatic cancer. Cancer Lett 1996;99:135-137.
26. Riley WM, Tautu C, Verazin G, et al. Evaluation of sialic acid concentration in serum for the diagnosis and staging of breast cancer. Clin Chim 1990;36:161-162.
27. Silver HKB, Karim KA, Salinas FA, Swenerton KD. Significance of sialic acid carcinoembryonic antigen as monitor of tumour burden among patients with carcinoma of ovary. Surg Gynecol Obstet 1981;153:209-213.
28. Feijoo C, Paez-de-la-Cadena MP, Rodriguez-Berrocal FJ, Martinez-Zorzano VS. Sialic acid levels in serum and tissue from colorectal cancer patients. Cancer Lett 1997;112: 155-160.
29. Romppanen J, Eskelinen M, Tikanoja S, Mononen I. Total and lipid bound serum sialic acid in benign and malignant breast disease. Anticancer Res 1997;17:1249-1253.
30. Tomaszewska R, Sonta-Jakimczyk-D, Dyduch A, Olejnik I, Mazur B. Sialic acid concentration in different stages of malignant lymphoma and leukemia in children. Acta Paediatr Jpn 1997;39:448-450.